US Stock MarketDetailed Quotes
ENLV Enlivex Therapeutics
- 1.140
- 0.0000.00%
Close Nov 29 13:00 ET
- 1.110
- -0.030-2.63%
Post 15:17 ET
25.07MMarket Cap-1163P/E (TTM)
1.170High1.101Low30.82KVolume1.170Open1.140Pre Close34.61KTurnover0.19%Turnover RatioLossP/E (Static)21.99MShares4.59052wk High0.94P/B18.39MFloat Cap0.81052wk Low--Dividend TTM16.13MShs Float44.900Historical High--Div YieldTTM6.05%Amplitude0.810Historical Low1.123Avg Price1Lot Size
Enlivex Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | 51.88%-2.62M | 74.41%-1.8M | 22.03%-4.51M | 1.80%-23.52M | -9.53%-5.28M | 17.50%-5.44M | 24.26%-7.02M | -76.93%-5.78M | -36.55%-23.95M | 26.90%-4.82M |
| Net income from continuing operations | 56.36%-2.6M | 54.42%-3.1M | 42.64%-4.14M | 6.41%-29.07M | -26.51%-9.1M | -4.01%-5.96M | 31.48%-6.79M | 12.24%-7.22M | -114.68%-31.06M | -51.79%-7.19M |
| Operating gains losses | 719.61%836K | -58.12%98K | -105.53%-77K | -118.31%-363K | -52,175.00%-2.09M | 103.52%102K | -91.99%234K | -29.20%1.39M | 135.47%1.98M | 99.88%-4K |
| Depreciation and amortization | -24.77%161K | -24.53%160K | -10.05%188K | 7.46%835K | -9.50%200K | 11.46%214K | 20.45%212K | 11.17%209K | 42.31%777K | 47.33%221K |
| Other non cash items | -50.00%108K | -63.27%83K | -52.88%98K | 494.46%4.94M | 1,982.52%4.29M | 0.93%216K | 0.00%226K | 12.43%208K | 101.21%831K | -5.94%206K |
| Change In working capital | -260.72%-1.5M | 140.31%570K | 4.56%-962K | -326.12%-1.82M | -14.44%1.02M | -135.68%-415K | 58.15%-1.41M | -155.11%-1.01M | 159.25%804K | 320.15%1.19M |
| -Change in prepaid assets | -363.69%-1.36M | 317.40%1.44M | -27.85%355K | 118.71%608K | 154.13%262K | -46.74%515K | 47.66%-661K | -53.50%492K | 122.26%278K | 24.14%-484K |
| -Change in payables and accrued expense | 91.27%-60K | -69.78%-764K | -2.88%-1.21M | -179.43%-1.47M | -59.24%845K | -331.31%-687K | 69.30%-450K | -224.37%-1.18M | 7,816.67%1.85M | 6,587.10%2.07M |
| -Change in other current liabilities | 67.49%-79K | 66.01%-103K | 67.60%-104K | 27.98%-955K | 77.89%-88K | -140.59%-243K | 53.38%-303K | -81.36%-321K | -1,478.57%-1.33M | -703.03%-398K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | 51.88%-2.62M | 74.41%-1.8M | 22.03%-4.51M | 1.80%-23.52M | -9.53%-5.28M | 17.50%-5.44M | 24.26%-7.02M | -76.93%-5.78M | -36.55%-23.95M | 26.90%-4.82M |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | -64.59%1.4M | 70.61%-794K | 116.26%5.1M | -141.53%-25.97M | 243.78%4.14M | -91.04%3.95M | 92.95%-2.7M | -152.53%-31.35M | 262.79%62.52M | 46.20%-2.88M |
| Net PPE purchase and sale | 89.66%-3K | -136.36%-16K | 179.01%128K | 98.73%-103K | 101.70%44K | 97.56%-29K | 101.29%44K | 82.98%-162K | -399.82%-8.12M | -149.85%-2.58M |
| Net investment purchase and sale | -109.21%-366K | 71.63%-779K | 115.77%4.92M | -136.61%-25.87M | 1,486.78%4.09M | -91.21%3.97M | 92.14%-2.75M | -151.44%-31.18M | 292.06%70.65M | 93.16%-295K |
| Net other investing changes | --1.77M | --1K | --53K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -64.59%1.4M | 70.61%-794K | 116.26%5.1M | -141.53%-25.97M | 243.78%4.14M | -91.04%3.95M | 92.95%-2.7M | -152.53%-31.35M | 262.79%62.52M | 46.20%-2.88M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 250K | 10,421.43%4.42M | 64.78%524K | 140.00%360K | 0 | 0 | -16.00%42K | 536.00%318K | -99.75%150K | 0 |
| Net common stock issuance | --250K | 10,421.43%4.42M | 64.78%524K | --360K | --0 | --0 | --42K | --318K | --0 | --0 |
| Proceeds from stock option exercised by employees | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | -98.08%150K | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | --250K | 10,421.43%4.42M | 64.78%524K | 140.00%360K | --0 | --0 | -16.00%42K | 536.00%318K | -99.75%150K | --0 |
| Net cash flow | ||||||||||
| Beginning cash position | 7.87%4.17M | -82.74%2.34M | -97.57%1.23M | 332.77%50.36M | -95.92%2.37M | -81.21%3.86M | -80.11%13.55M | 332.77%50.36M | 65.94%11.64M | 148.86%58.05M |
| Current changes in cash | 35.07%-970K | 118.88%1.83M | 103.02%1.11M | -226.88%-49.13M | 85.16%-1.14M | -103.98%-1.49M | 79.63%-9.68M | -165.21%-36.81M | 669.50%38.72M | 35.56%-7.69M |
| Effect of exchange rate changes | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | --0 | ---- |
| End cash Position | 34.97%3.2M | 7.87%4.17M | -82.74%2.34M | -97.57%1.23M | -97.57%1.23M | -95.92%2.37M | -81.21%3.86M | -80.11%13.55M | 332.77%50.36M | 332.77%50.36M |
| Free cash flow | 51.98%-2.63M | 74.32%-1.81M | 23.43%-4.55M | 25.93%-23.76M | 28.58%-5.28M | 29.74%-5.47M | 44.28%-7.06M | -40.87%-5.95M | -67.34%-32.08M | 2.95%-7.4M |
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data